Genmab A/S

Genmab A/S

Genmab A/S

Overview
Date Founded

1999

Headquarters

Kalvebod Brygge 43,Copenhagen, Capital Region 1560

Type of Company

Public

Employees (Worldwide)

781

Industries

Pharmaceuticals
Industrial Machinery & Manufacturing
Medical Support Services
Biotechnology
Wholesale: Medical Supplies & Pharmaceuticals
Hospitals & Patient Services

Company Description

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Contact Data
Trying to get in touch with decision makers at Genmab A/S? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Co-Founder

Executive Vice President & Chief Financial Officer

Executive Vice President & Chief Operating Officer

Executive Vice President & Chief Development Officer

Senior Vice President, Head of Global IPR & Legal

Executive Vice President & Chief Medical Officer, Head of Experimental Medicines

Director & Vice President, Head of Regulatory Affairs

Senior Vice President, Corporate Strategy & Planning

Senior Vice President, Global Communications & Investor Relations

Senior Vice President, Global Human Resources

Board of Directors

Director-Public Health Policy Council at Harvard University

Former President & Chief Executive Officer at TDC Group

Advisor at Ember Technologies, Inc.

Adjunct Professor for Strategy & Entrepreneurship at The University of North Carolina, Chapel Hill - Kenan-Flagler Business School

Director at Hansa Biopharma AB

Chief Executive Officer & Director at Gammadelta Therapeutics Ltd.

Professional at Genmab A/S

Professional at Genmab A/S

Director & Vice President, Head of Regulatory Affairs at Genmab A/S

Paths to Genmab A/S
Potential Connections via
Relationship Science
You
Genmab A/S
Owners & Shareholders
Details Hidden

APLP focuses exclusively on active, high value-added investment strategies where experienced investment professionals pursue superior results through a combination of original thinking and a disciplined investment approach based on a bottom-up process that covers a range of geographic areas and focuses on investments in growth and value stocks. The firm places particular emphasis on identifying and investing in well-managed companies with dominant or increasing market shares. They also closely monitor market valuation. Their autonomous investment teams oversee a range of investment strategies across diversified market capitalizations, regions and styles. All accounts managed by the firm regardless of investment strategy, invest primarily in common stocks and other equity securities. Their distribution strategy is focused on sophisticated investors around the globe that operate with institutional decision-making processes and longer-term investment horizons.

Details Hidden

GQG Partners is a long-term investor that aims to deliver superior risk-adjusted returns and capital appreciation over a full market cycle by investing primarily in the equity securities of both US and non-US issuers that they believe have durable earnings potential that is undervalued by the market. Their portfolios are diversified by country and sector, but are not constrained by any benchmark index. The firm typically invests in common and preferred stock and other publicly traded equity securities. With an investment horizon of five years, portfolio holdings tend to be stable over time. GQG Partners pursues a bottom-up fundamental research process to stock selection. The firm sells companies when their risks or opportunities fundamentally changes, or when the stock price no longer reflects a good value. They will also sell companies when they find more attractive alternatives.

Details Hidden

Candriam is an active, growth-oriented manager which offers conviction-driven investment strategies in five main areas: fixed-income, equities, alternatives, sustainable investments and asset allocation. They primarily invest in European equities, favoring large-cap companies. The firm employs a methodical investment process that relies on fundamental and solid in-house analysis which aims to generate consistent long-term investment returns. Their investment products cover a range of investment objectives and strategies. In-house research combines fundamental analysis and proprietary, quantitative models. Candriam selects equities utilizing both top-down and bottom-up approaches. Their top-down approach analyzes economic scenarios and key consensus data, seeking to capture the rates of return and level of risk for each asset class and geographic region.

Recent Transactions
Details Hidden

Genmab A/S issued DKK Ordinary Shares

Transaction Advisors
Underwriter

Advised onGenmab A/S issued DKK Ordinary Shares

Underwriter

Advised onGenmab A/S issued DKK Ordinary Shares

Legal Advisor

Advised onBaxter Healthcare Corporation, Baxter International, Inc. purchase Genmab A/S /Non-Plasma-Derived Antibody Manufacturing Ops from Genmab A/S

Advisors & Consultants
Advisor

Former Senior Vice President-Investor Relations & Communications at Genmab A/S

Clients

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the discovery, development, manufacture and sale of a line of proprietary pharmaceutical products. It is focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; as well as other serious health conditions. The company was founded on 2013 and is headquartered in North Chicago, IL.

H. Lundbeck A/S engages in the research, development, and market of pharmaceutical products for the treatment of psychiatric and neurological disorders. It operates through the following geographical segments: Europe, the Unites States of America, and International Markets. Its product portfolio targets the following diseases: Alzheimer's, depression, Parkinson's, Schizophrenia, alcohol dependence, anxiety, bipolar disorder, epilepsy, and Huntington's. The company was founded by Hans Lundbeck on August 14, 1915 and is headquartered in Valby, Denmark.

Key Stats and Financials As of 2020
Market Capitalization
$28.8B
Total Enterprise Value
$22B
Earnings Per Share
$10.97
Enterprise Value / Sales
14.49x
TEVNet Income
30.79x
EBITDAMargin
64.87%
Enterprise Value EBITDAOperating
22.34x
Debt TEV
0x
Three Year Compounded Annual Growth Rate Of Revenue
62.29%
Revenue
$1.52B
Total Equity
$2.87B
Total Debt
$47.9M
Net Profit
$715M
EBITDA
$985M
Investors
Details Hidden

Co-Founder & Partner at Medicxi Ventures (Jersey) Ltd.

Suppliers
Bristol-Myers Squibb Company Medical Support Services | New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Seagen Inc. Pharmaceuticals | Bothell, WA

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Amgen, Inc. Hospitals & Patient Services | Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government. Johnson & Johnson is headquartered in New Brunswick, New Jersey, the consumer division being located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in 60 countries and products sold in over 175 countries. Johnson & Johnson had worldwide sales of $82.6 billion during calendar year 2020. Johnson & Johnson's brands include numerous household names of medications and first aid supplies. Among its well-known consumer products are the Band-Aid Brand line of bandages, Tylenol medications, Johnson's Baby products, Neutrogena skin and beauty products, Clean & Clear facial wash and Acuvue contact lenses. Johnson & Johnson's pharmaceutical arm is Janssen Pharmaceutica.

MacroGenics, Inc. Pharmaceuticals - Rockville, MD

MacroGenics is a leader in the discovery and development of innovative medicinces that utilize our next generation antibody-based technologies. Our team of 150+ dedicated individuals is advancing a pipeline of product candidates to treat patients with cancer and other serious, complex diseases. Our products and platforms have attracted multiple partnerships with leading pharmaceutical companies around the globe. Our innovative product candidates leverage our fully-integrated capabilities around the discovery, development, and production of antibodies and incorporate three proprietary technology platforms: Our Dual-Affinity Re-Targeting (DART™) platform enables us to design candidate therapeutics that target multiple disease-causing cells or redundant disease-associated pathways with a single molecule; Our Fc Optimization platform enhances the natural immune system's ability to mediate killing of cancer cells; and Our Cancer Stem Cell platform provides new approaches to target cancers unresponsive to current therapy.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Genmab A/S. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Genmab A/S's profile does not indicate a business or promotional relationship of any kind between RelSci and Genmab A/S.